H Wildiers

Summary

Affiliation: University Hospitals Leuven
Country: Belgium

Publications

  1. ncbi Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
    Hans Wildiers
    Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:1101-15. 2007
  2. ncbi Issues in the adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age >70)
    H Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Ann Oncol 23:x339-41. 2012
  3. ncbi Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence
    H Wildiers
    Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium
    Breast Cancer Res Treat 114:103-12. 2009
  4. ncbi A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients
    Hans Wildiers
    Multidisciplinary Breast Centre, University Hospital Gasthuisberg, KU Leuven, Belgium
    Crit Rev Oncol Hematol 67:133-8. 2008
  5. ncbi Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
    Hans Wildiers
    Multidisciplinary Breast Centre, University Hospital Gasthuisberg, Leuven, Belgium
    Crit Rev Oncol Hematol 77:221-40. 2011
  6. ncbi Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
    H Wildiers
    Department of General Medical Oncology Multidisciplinary Breast Centre, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
    Breast Cancer Res Treat 123:463-9. 2010
  7. ncbi Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer
    H Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Ann Oncol 22:588-94. 2011
  8. ncbi Mastering chemotherapy dose reduction in elderly cancer patients
    Hans Wildiers
    Department of General Medical Oncology Multidisciplinary Breast Centre, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 43:2235-41. 2007
  9. ncbi Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care
    Hans Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    J Pain Symptom Manage 38:124-33. 2009
  10. ncbi Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer
    B Brouwers
    Multidisciplinary Breast Centre, Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Tumour Biol 29:211-6. 2008

Collaborators

Detail Information

Publications50

  1. ncbi Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
    Hans Wildiers
    Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Lancet Oncol 8:1101-15. 2007
    ..The available evidence was reviewed and synthesised to provide consensus recommendations regarding the care of breast cancer in older adults...
  2. ncbi Issues in the adjuvant treatment of common tumors (with a focus on breast cancer) in older adults (age >70)
    H Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Ann Oncol 23:x339-41. 2012
    ..age-related physiological changes can decrease tolerance of classical chemotherapy regimens, indicating the need for close monitoring and preventive measures...
  3. ncbi Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence
    H Wildiers
    Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium
    Breast Cancer Res Treat 114:103-12. 2009
    ....
  4. ncbi A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients
    Hans Wildiers
    Multidisciplinary Breast Centre, University Hospital Gasthuisberg, KU Leuven, Belgium
    Crit Rev Oncol Hematol 67:133-8. 2008
    ..SRI may be a useful tool in the follow-up of elderly patients treated with anthracyclines, allowing early initiation of preventive measures in order to prevent further irreversible cardiac damage...
  5. ncbi Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma
    Hans Wildiers
    Multidisciplinary Breast Centre, University Hospital Gasthuisberg, Leuven, Belgium
    Crit Rev Oncol Hematol 77:221-40. 2011
    ..The definition of "full dose" is, however, unclear. Older age and higher disease stage may be associated with reduced RDI, and G-CSF improved the chances of higher RDI in most studies...
  6. ncbi Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
    H Wildiers
    Department of General Medical Oncology Multidisciplinary Breast Centre, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
    Breast Cancer Res Treat 123:463-9. 2010
    ..Furthermore, toxicity was significant...
  7. ncbi Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer
    H Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Ann Oncol 22:588-94. 2011
    ..To evaluate capecitabine-docetaxel (XT), with trastuzumab (H) in human epidermal growth factor receptor 2 (HER2)-positive disease, in inoperable locally advanced breast cancer (LABC)...
  8. ncbi Mastering chemotherapy dose reduction in elderly cancer patients
    Hans Wildiers
    Department of General Medical Oncology Multidisciplinary Breast Centre, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 43:2235-41. 2007
    ..Each of these topics will be reviewed here trying to give concrete recommendations for clinical practice...
  9. ncbi Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care
    Hans Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    J Pain Symptom Manage 38:124-33. 2009
    ..9 hours. These data suggest that there are no significant differences in effectiveness or survival time among atropine, hyoscine butylbromide, and scopolamine in the treatment of death rattle...
  10. ncbi Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer
    B Brouwers
    Multidisciplinary Breast Centre, Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Tumour Biol 29:211-6. 2008
    ..It is mainly a clinical diagnosis. The aim of this study was to compare IBC to clinically diagnosed noninflammatory locally advanced nonmetastatic breast cancer, also called cLABC...
  11. ncbi Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers
    O Brouckaert
    Multidisciplinary Breast Centre, University Hospital Leuven, Leuven, Belgium
    Ann Oncol 23:2578-84. 2012
    ..We here applied the 2011 St Gallen surrogate definition for breast cancer subclassification using tumor grade instead of Ki67...
  12. ncbi Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs
    A Smeets
    Multidisciplinary Breast Centre University Hospital, Herestraat 49, B 3000 Leuven, Belgium
    Breast Cancer Res Treat 129:767-76. 2011
    ..Moreover, our data suggest a general deregulation of the miRNA machinery that is potentially responsible for lymph node invasion...
  13. ncbi Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients
    T Vandorpe
    Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium
    Breast Cancer Res Treat 128:429-35. 2011
    ..The mildly higher incidence of ALN metastasis in lobular cancers in univariable analysis is not due to the lobular subtype, but due to confounding factors that interact with lymph node involvement...
  14. ncbi Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer
    P Neven
    Department of Obstetrics and Gynaecology, Multidisciplinary Breast Centre, University Hospitals Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Breast Cancer Res Treat 110:153-9. 2008
    ..The negative association between the oestrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER-2) in breast cancer travels in both directions. ER+ tumours are less likely HER-2+ and HER-2+ tumours are less likely ER+...
  15. ncbi Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1
    S Pintens
    Department of Pathology, UZ Leuven, Leuven, Belgium
    J Clin Pathol 62:624-8. 2009
    ..The aim of this study was to investigate to what extent CK5/6 and HER-1 characterise the group of triple negative breast cancers...
  16. ncbi Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data
    A Lintermans
    Department of Obstetrics and Gynecology, KU Leuven, Leuven, Belgium
    Ann Oncol 24:350-5. 2013
    ..Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data...
  17. ncbi Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view
    P Neven
    Multidisciplinary Breast Center Department of Obstetrics and Gynecology, UZ Leuven, Catholic University Leuven, Leuven, Belgium
    Int J Gynecol Cancer 16:505-10. 2006
  18. ncbi Matrix metalloproteinase expression patterns in luminal A type breast carcinomas
    J Decock
    Laboratory for Experimental Oncology LEO, Department of General Medical Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Dis Markers 23:189-96. 2007
    ..The current study aimed at defining an RNA expression profile of various MMPs in breast cancer and correlating their expression with clinicopathological parameters...
  19. ncbi Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age
    T Van Mieghem
    Department of Obstetrics and Gynaecology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
    Breast Cancer Res Treat 106:127-33. 2007
    ..It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression...
  20. ncbi Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis
    A Lintermans
    Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospitals Leuven, Belgium
    Ann Oncol 22:1763-9. 2011
    ..Here, we report the final results and assess the relationship between grip strength and body mass index (BMI)...
  21. ncbi Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users
    A S Dieudonné
    Department of Obstetrics and Gynecology, University Hospital Leuven, Herestraat 49, 3000, Leuven, Belgium
    Breast Cancer Res Treat 118:531-8. 2009
    ..They support clinical trials prospectively testing the effect of CYP2D6 genetic variability in response to tamoxifen before denying this drug to breast cancer patients only based on their CYP2D6*4 status...
  22. ncbi A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis
    B Leyssens
    Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium
    Ann Oncol 21:419-23. 2010
    ..We investigate the efficacy of eyedrops containing corticosteroids (CS) versus artificial tears (AT) in patients receiving weekly docetaxel in the prevention of dacryostenosis...
  23. ncbi Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables
    J Decock
    Laboratory for Experimental Oncology (LEO, Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Exp Metastasis 22:495-502. 2005
    ..However, this increase was too small to be of clinical use. Furthermore, no relationship was found between plasma gelatinase levels, total or active, and any of the clinicopathological prognostic factors...
  24. ncbi A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    R Paridaens
    Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Borst Centrum, Belgium
    Cancer Chemother Pharmacol 70:503-11. 2012
    ..To determine the recommended dose (RD) of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and to investigate potential pharmacokinetic (PK) interactions...
  25. ncbi Challenges in treating older cancer patients: breast cancer
    H Wildiers
    Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    Ann Oncol 19:vii99-103. 2008
  26. ncbi Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer
    Ruxandra Jurcut
    Department of Cardiovascular Diseases, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium
    J Am Soc Echocardiogr 21:1283-9. 2008
    ..Doppler myocardial imaging-based velocity, strain, and strain rate measurements have been shown to sensitively quantify abnormalities in cardiac function in other settings...
  27. ncbi Pharmacology of anticancer drugs in the elderly population
    Hans Wildiers
    Laboratory of Experimental Oncology, and Department of Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Pharmacokinet 42:1213-42. 2003
    ..This review attempts to elucidate the factors that can influence the pharmacokinetics of anticancer drugs frequently used in the elderly, and the clinical or biochemical parameters that form the basis for dose adjustments with age...
  28. ncbi Detection and monitoring of cardiotoxicity-what does modern cardiology offer?
    Ruxandra Jurcut
    Department of Cardiology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000, Leuven, Belgium
    Support Care Cancer 16:437-45. 2008
    ..The use of new biomarkers like B-type natriuretic peptide and troponin and less often used imaging techniques like magnetic resonance imaging and computed tomography will also be mentioned...
  29. ncbi Triple-negative breast cancer
    Gert Stockmans
    Department of Internal Medicine, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium
    Curr Opin Oncol 20:614-20. 2008
    ..We would like to describe recent pathological and genetic advancements and their possible implications on the development of new treatment strategies...
  30. ncbi Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence
    H Wildiers
    Laboratory of Experimental Oncology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 40:284-90. 2004
    ..Mechanisms other than trapping are likely to be involved in the chemosensitising capacity of CA4DP...
  31. ncbi Adjuvant chemotherapy in elderly patients with breast cancer: where are we?
    Hans Wildiers
    Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Belgium
    Curr Opin Oncol 17:566-72. 2005
    ..This review summarizes the current knowledge and provides guidelines for the use of adjuvant chemotherapy in elderly patients with breast cancer...
  32. ncbi Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology
    Benoit Beuselinck
    Medical Oncology Department, Catholic University Leuven, University Hospitals Leuven, Herestraat 49, Leuven, Belgium
    Crit Rev Oncol Hematol 75:70-7. 2010
    ..They display different, but acceptable toxicity profiles, with levels of antitumoral efficacy comparable to those previously reported for 3-weekly regimens...
  33. ncbi Taxanes in elderly breast cancer patients
    Hans Wildiers
    Department of Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, Leuven B 3000, Belgium
    Cancer Treat Rev 30:333-42. 2004
    ..In general however, weekly taxanes are a reasonable option for older patients with metastatic breast cancer...
  34. ncbi Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study
    Robert Paridaens
    Department of Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium
    Anticancer Drugs 15:341-6. 2004
    ....
  35. ncbi Relationship between age and axillary lymph node involvement in women with breast cancer
    Hans Wildiers
    Multidisciplinary Breast Centre and Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium
    J Clin Oncol 27:2931-7. 2009
    ..To study the relation between the presence of axillary lymph node (LN) involvement and age in breast cancer...
  36. ncbi Death rattle: prevalence, prevention and treatment
    Hans Wildiers
    Department of Oncology, Gasthuisberg University Hospital Leuven, Leuven, Belgium
    J Pain Symptom Manage 23:310-7. 2002
    ..Administration of subcutaneous hyoscine hydrobromide, as a bolus or continuous infusion, is effective therapy for real DR and is comfortable for the patient and caregivers...
  37. ncbi Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant
    Leilani Morales
    Department of Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium
    Breast Cancer Res Treat 117:77-81. 2009
    ..Furthermore, no new uterine pathologies were detected, indicating that fulvestrant behaves as a pure antiestrogen at the uterine level...
  38. ncbi Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    Ben Van Calster
    Multidisciplinary Breast Centre, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
    Breast Cancer Res Treat 113:181-7. 2009
    ..To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status...
  39. ncbi Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer
    Toon Maes
    Department of General Medical Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Breast Cancer Res Treat 110:135-42. 2008
    ..In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity...
  40. ncbi Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model
    Hans Wildiers
    Laboratory of Experimental Oncology LEO, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Anticancer Res 23:4055-9. 2003
    ..Great care is required when combining nicotinamide with anticancer drugs, since unexpected pharmacokinetic and pharmacodynamic alterations might occur...
  41. ncbi Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors
    Olivier Brouckaert
    Multidisciplinary Breast Centre, UZLeuven, Leuven 3000, Belgium
    Breast Cancer Res Treat 115:349-58. 2009
    ..We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype...
  42. ncbi Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging
    Leilani Morales
    Department of General Medical Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Breast Cancer Res Treat 104:87-91. 2007
    ..However, the pathogenesis and anatomic correlate of musculoskeletal pains have not been thoroughly evaluated. Moreover, the impact of AI-induced musculoskeletal symptoms on normal daily functioning needs to be further explored...
  43. ncbi Fertility preservation in (breast) cancer patients: is it safe?
    Hans Wildiers
    J Clin Oncol 24:5335-6; author reply 5337-8. 2006
  44. ncbi International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency
    Stuart M Lichtman
    Memorial Sloan Kettering Cancer Centre, New York, USA
    Eur J Cancer 43:14-34. 2007
    ..Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are needed in order to maximise efficacy whilst avoiding unacceptable toxicity...
  45. ncbi Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer
    Robert Paridaens
    Universitair Ziekenhuis Gasthuisberg, Katholieke Universiteit Leuven, Belgium
    Clin Breast Cancer 7:861-6. 2007
    ..Pemetrexed and epirubicin are each active in patients with advanced/metastatic breast cancer (MBC). This phase I/II study evaluated these drugs as a combination regimen...
  46. ncbi Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related
    Huei-Jean Huang
    Division of Gynaecologic Oncology in Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Breast Cancer Res Treat 91:81-7. 2005
    ..518). The study confirms an age-related inverse relationship between HER-2/neu and PR only in women age>45 years but not in women age<or=45 years...
  47. ncbi International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature
    Stuart M Lichtman
    Memorial Sloan Kettering Cancer Center, Commack, New York 11725, USA
    J Clin Oncol 25:1832-43. 2007
    ..In addition, data already accumulated need to be reanalyzed by age to aid in the management of the older cancer patient...
  48. ncbi Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR
    Mohamed Saad Ismail
    Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium and National Cancer Institute, Cairo, Egypt
    Clin Cancer Res 10:196-201. 2004
    ..However, no significant correlation between the presence of CK19+ cells in BM and PB and classical prognostic factors was found. We detected no statistically significant influence of surgical manipulation on CK19+ cells...
  49. ncbi Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    Leen De Maeyer
    J Clin Oncol 26:335-6; author reply 336-8. 2008
  50. ncbi In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement
    Patrick Neven
    J Clin Oncol 26:1768-9; author reply 1769-71. 2008